Health Care · Surgical & Medical Instruments & Apparatus

BAX Baxter International SEC Filings & Insider Trading Activity 2026

company
CIK 1045695 filings
S&P 500

BAX at a glance

Baxter International (BAX, SEC CIK 10456) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Baxter International (BAX) reported revenue of $11.2 billion (up 5.7% from FY2024) and a net loss of $957.0 million. Diluted EPS was -$1.87.
  • As of September 30, 2026, 41 institutional investment managers tracked by SignalX reported holding Baxter International (BAX) shares worth $5.0 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$11.2B
+5.7% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
41 funds
$5.0B · +2 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: diversified healthcare products including IV solutions, infusion systems, parenteral nutrition, surgical and respiratory devices
  • New segment structure: three reportable segments as of Q3 2023; Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals
  • Strategic shift: completed sale of Kidney Care business for $3.71B net proceeds and BioPharma Solutions for $3.96B, focusing on streamlined operations
  • Debt reduction: repaid $3.81B legacy debt primarily from Kidney Care sale and additional repayments using BioPharma sale proceeds
  • Geographic footprint: products manufactured in 20+ countries and sold in 100+ countries, reinforcing global healthcare access

Risk Factors

  • FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations
  • Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified
  • Supply chain disruptions including manufacturing, sterilization, and distribution difficulties causing product availability risks
  • Competition risk from technology advances and changing consumer preferences potentially impairing new product monetization
  • Significant indebtedness requiring substantial cash flow allocation for debt service, limiting growth strategy and R&D investments

Management Discussion & Analysis

  • Kidney Care business sold for $3.80B cash, net after-tax proceeds approx. $3.3B completed Jan 31, 2025
  • Legacy indebtedness of $3.81B repaid in 2025, excluding $2.00B repaid from new notes offering
  • Kidney Care segment results reported as discontinued operations, prior periods restated accordingly
  • Cost restructuring initiated due to dis-synergies from reduced company size post-sale
  • No explicit revenue, profitability, or forward guidance disclosed in provided text

AI summary of the BAX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in Baxter’s 2025 Annual Report

Management Discussion & Analysis

  • Revenue $2.976B, up $141M from $2.835B YoY, with Medical Products & Therapies strongest at 6% growth
  • Gross margin 33.4% vs 33.5% YoY, excluding special items down 1.1 percentage points
  • Advanced Surgery best-performing line, sales up 12%; Other sales weakest, $68M vs $85M YoY
  • Operating cash flow $1.07B vs $355M YoY; debt repayments $600M and capital expenditures $363M
  • Outlook: tariffs, supply constraints, inflation and geopolitical uncertainty remain headwinds; no meaningful Novum LVP sales during shipment holds

AI summary of the BAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor presentation shared with certain stockholders beginning November 19, 2026
  • Reg FD disclosure signals ongoing shareholder engagement, potentially addressing strategy or investor concerns

Item EX-99.1: Item EX-99.1

  • FY2026 organic sales growth guidance raised to 3%-4%, versus GAAP sales growth guidance of 4%-5%
  • Free cash flow reached $705 million through September 30, 2026, supporting balance-sheet repair
Filed Oct 29, 2026Full analysis →

Item 8.01: Other Events

  • Quarterly cash dividend maintained at $0.01 per share
  • January 4, 2027 payment date for shareholders of record November 27, 2026

Item EX-99.1: Item EX-99.1

  • Q3 sales $2.98B, up 5% reported and organically, with growth across all segments and divisions
  • GAAP diluted EPS $0.57 versus $(0.10) last year, while adjusted EPS fell 16% to $0.58

Item 2.02: Results of Operations and Financial Condition

  • Earnings release covers the quarter ended September 30, 2026
  • Exhibit 99.1 contains Baxter’s financial results and management commentary
Filed Aug 19, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • John Rogers appointed CFO effective October 1, 2026, replacing the current finance leadership
  • Medtech finance executive brings transformation experience from Smith+Nephew and WPP

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • John Rogers appointed CFO effective October 1, 2026, following leadership roles at Smith+Nephew and WPP
  • CFO compensation includes $925,000 salary, 100% target bonus, and $4,000,000 annual equity target

Item 7.01: Regulation FD Disclosure

  • CFO appointment of Mr. Rogers announced on August 19, 2026
  • Leadership change potentially affects capital allocation, financial reporting and investor communications

AI summaries of BAX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BAX

Don't miss the next BAX filing

  • Alerts as it files. A push when BAX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BAX, by share count.
  • Ask anything. An AI agent that reads every BAX filing and answers with sources.

BAX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Foster JulieFSep 2, 2026$25.70
Hider Andrew P.FSep 2, 2026$25.70
Teaff JamesFSep 1, 2026$25.48
Wallace Steven P.FJun 2, 2026$18.68
Teaff JamesFJun 2, 2026$18.68
Zielinski Anita AAJun 1, 2026-
Ampofo William A. IIAMay 5, 2026-
Craig Jeffrey AAMay 5, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$10.6B$11.2B
Gross Profit$5.0B$4.0B$3.4B
Operating Income-$14.0M-$308.0M
Net Income$2.7B-$649.0M-$957.0M
Gross Margin-37.5%30.1%
Op. Margin-0.1%-2.7%
Net Margin--6.1%-8.5%
Balance Sheet
Total Assets$28.3B$25.8B$20.1B
Equity-$7.0B$6.1B
ROE--9.3%-15.6%
Per Share
EPS$5.25$-1.27$-1.87
Cash Flow
Operating CF-$1.0B$845.0M

Source: XBRL data in Baxter International (BAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BAX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BAX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202641$5.00B
Q2 202639$5.78B
Q1 202637$4.34B
Q4 202536$4.91B
Q3 202538$5.52B
Q2 202538$7.41B
Q1 202535$5.25B
Q4 202432$3.97B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 296 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BAX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
8-KAug 19, 2026Analysis-
8-KAug 18, 2026Analysis-
8-KAug 4, 2026Analysis-
8-KAug 4, 2026Analysis-
8-KJul 30, 2026Analysis-
10-QJul 30, 2026Analysis
8-KJul 14, 2026Analysis-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
8-KMay 8, 2026Analysis
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-

Related Health Care companies

All Health Care →

BAX SEC filings: frequently asked questions

Which institutions hold BAX stock?

As of September 30, 2026, the largest Baxter International (BAX) holders among the 13F filers tracked by SignalX were BlackRock ($1.6 billion), Vanguard Capital Management LLC ($813.7 million), Vanguard Portfolio Management LLC ($562.0 million), State Street Corp ($495.2 million), Invesco Ltd ($271.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BAX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Baxter International (BAX) reported revenue of $11.2 billion (up 5.7% from FY2024) and a net loss of $957.0 million. Diluted EPS was -$1.87. The figures come from the XBRL data in the 10-K.

What are the main risks in BAX's latest 10-K?

In the 10-K filed February 12, 2026, Baxter International (BAX) flagged: FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations. Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified. (AI summary of the Risk Factors section.)

What did BAX report in its latest 8-K?

Baxter International (BAX) filed an 8-K on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation shared with certain stockholders beginning November 19, 2026.

What are the latest BAX SEC filings?

Baxter International (BAX) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on September 3, 2026.

What is BAX's SEC CIK number?

Baxter International (BAX)'s SEC Central Index Key (CIK) is 10456. EDGAR lists every BAX filing under that number.

Ask anything about BAX

The research agent reads BAX's filings, financials, insider trades and 13F holders, then answers with sources.